Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

Fiona M. Behan, Francesco Iorio, Gabriele Picco, Emanuel Gonçalves, Charlotte M. Beaver, Giorgia Migliardi, Rita Santos, Yanhua Rao, Francesco Sassi, Marika Pinnelli, Rizwan Ansari, Sarah Harper, David Adam Jackson, Rebecca McRae, Rachel Pooley, Piers Wilkinson, Dieudonne van der Meer, David Dow, Carolyn Buser-Doepner, Andrea Bertotti & 5 others Livio Trusolino, Euan A. Stronach, Julio Saez-Rodriguez, Kosuke Yusa, Mathew J. Garnett

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Functional genomics approaches can overcome limitations—such as the lack of identification of robust targets and poor clinical efficacy—that hamper cancer drug development. Here we performed genome-scale CRISPR–Cas9 screens in 324 human cancer cell lines from 30 cancer types and developed a data-driven framework to prioritize candidates for cancer therapeutics. We integrated cell fitness effects with genomic biomarkers and target tractability for drug development to systematically prioritize new targets in defined tissues and genotypes. We verified one of our most promising dependencies, the Werner syndrome ATP-dependent helicase, as a synthetic lethal target in tumours from multiple cancer types with microsatellite instability. Our analysis provides a resource of cancer dependencies, generates a framework to prioritize cancer drug targets and suggests specific new targets. The principles described in this study can inform the initial stages of drug development by contributing to a new, diverse and more effective portfolio of cancer drug targets.

Original languageEnglish
Pages (from-to)511-516
Number of pages6
JournalNature
Volume568
Issue number7753
DOIs
Publication statusPublished - Apr 25 2019

Fingerprint

Neoplasms
Pharmaceutical Preparations
Therapeutics
Microsatellite Instability
Genomics
Biomarkers
Genotype
Genome
Cell Line

ASJC Scopus subject areas

  • General

Cite this

Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., ... Garnett, M. J. (2019). Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. Nature, 568(7753), 511-516. https://doi.org/10.1038/s41586-019-1103-9

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. / Behan, Fiona M.; Iorio, Francesco; Picco, Gabriele; Gonçalves, Emanuel; Beaver, Charlotte M.; Migliardi, Giorgia; Santos, Rita; Rao, Yanhua; Sassi, Francesco; Pinnelli, Marika; Ansari, Rizwan; Harper, Sarah; Jackson, David Adam; McRae, Rebecca; Pooley, Rachel; Wilkinson, Piers; van der Meer, Dieudonne; Dow, David; Buser-Doepner, Carolyn; Bertotti, Andrea; Trusolino, Livio; Stronach, Euan A.; Saez-Rodriguez, Julio; Yusa, Kosuke; Garnett, Mathew J.

In: Nature, Vol. 568, No. 7753, 25.04.2019, p. 511-516.

Research output: Contribution to journalArticle

Behan, FM, Iorio, F, Picco, G, Gonçalves, E, Beaver, CM, Migliardi, G, Santos, R, Rao, Y, Sassi, F, Pinnelli, M, Ansari, R, Harper, S, Jackson, DA, McRae, R, Pooley, R, Wilkinson, P, van der Meer, D, Dow, D, Buser-Doepner, C, Bertotti, A, Trusolino, L, Stronach, EA, Saez-Rodriguez, J, Yusa, K & Garnett, MJ 2019, 'Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens', Nature, vol. 568, no. 7753, pp. 511-516. https://doi.org/10.1038/s41586-019-1103-9
Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G et al. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. Nature. 2019 Apr 25;568(7753):511-516. https://doi.org/10.1038/s41586-019-1103-9
Behan, Fiona M. ; Iorio, Francesco ; Picco, Gabriele ; Gonçalves, Emanuel ; Beaver, Charlotte M. ; Migliardi, Giorgia ; Santos, Rita ; Rao, Yanhua ; Sassi, Francesco ; Pinnelli, Marika ; Ansari, Rizwan ; Harper, Sarah ; Jackson, David Adam ; McRae, Rebecca ; Pooley, Rachel ; Wilkinson, Piers ; van der Meer, Dieudonne ; Dow, David ; Buser-Doepner, Carolyn ; Bertotti, Andrea ; Trusolino, Livio ; Stronach, Euan A. ; Saez-Rodriguez, Julio ; Yusa, Kosuke ; Garnett, Mathew J. / Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. In: Nature. 2019 ; Vol. 568, No. 7753. pp. 511-516.
@article{34ccd6ec0149495cb6972d677875d2f0,
title = "Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens",
abstract = "Functional genomics approaches can overcome limitations—such as the lack of identification of robust targets and poor clinical efficacy—that hamper cancer drug development. Here we performed genome-scale CRISPR–Cas9 screens in 324 human cancer cell lines from 30 cancer types and developed a data-driven framework to prioritize candidates for cancer therapeutics. We integrated cell fitness effects with genomic biomarkers and target tractability for drug development to systematically prioritize new targets in defined tissues and genotypes. We verified one of our most promising dependencies, the Werner syndrome ATP-dependent helicase, as a synthetic lethal target in tumours from multiple cancer types with microsatellite instability. Our analysis provides a resource of cancer dependencies, generates a framework to prioritize cancer drug targets and suggests specific new targets. The principles described in this study can inform the initial stages of drug development by contributing to a new, diverse and more effective portfolio of cancer drug targets.",
author = "Behan, {Fiona M.} and Francesco Iorio and Gabriele Picco and Emanuel Gon{\cc}alves and Beaver, {Charlotte M.} and Giorgia Migliardi and Rita Santos and Yanhua Rao and Francesco Sassi and Marika Pinnelli and Rizwan Ansari and Sarah Harper and Jackson, {David Adam} and Rebecca McRae and Rachel Pooley and Piers Wilkinson and {van der Meer}, Dieudonne and David Dow and Carolyn Buser-Doepner and Andrea Bertotti and Livio Trusolino and Stronach, {Euan A.} and Julio Saez-Rodriguez and Kosuke Yusa and Garnett, {Mathew J.}",
year = "2019",
month = "4",
day = "25",
doi = "10.1038/s41586-019-1103-9",
language = "English",
volume = "568",
pages = "511--516",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7753",

}

TY - JOUR

T1 - Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

AU - Behan, Fiona M.

AU - Iorio, Francesco

AU - Picco, Gabriele

AU - Gonçalves, Emanuel

AU - Beaver, Charlotte M.

AU - Migliardi, Giorgia

AU - Santos, Rita

AU - Rao, Yanhua

AU - Sassi, Francesco

AU - Pinnelli, Marika

AU - Ansari, Rizwan

AU - Harper, Sarah

AU - Jackson, David Adam

AU - McRae, Rebecca

AU - Pooley, Rachel

AU - Wilkinson, Piers

AU - van der Meer, Dieudonne

AU - Dow, David

AU - Buser-Doepner, Carolyn

AU - Bertotti, Andrea

AU - Trusolino, Livio

AU - Stronach, Euan A.

AU - Saez-Rodriguez, Julio

AU - Yusa, Kosuke

AU - Garnett, Mathew J.

PY - 2019/4/25

Y1 - 2019/4/25

N2 - Functional genomics approaches can overcome limitations—such as the lack of identification of robust targets and poor clinical efficacy—that hamper cancer drug development. Here we performed genome-scale CRISPR–Cas9 screens in 324 human cancer cell lines from 30 cancer types and developed a data-driven framework to prioritize candidates for cancer therapeutics. We integrated cell fitness effects with genomic biomarkers and target tractability for drug development to systematically prioritize new targets in defined tissues and genotypes. We verified one of our most promising dependencies, the Werner syndrome ATP-dependent helicase, as a synthetic lethal target in tumours from multiple cancer types with microsatellite instability. Our analysis provides a resource of cancer dependencies, generates a framework to prioritize cancer drug targets and suggests specific new targets. The principles described in this study can inform the initial stages of drug development by contributing to a new, diverse and more effective portfolio of cancer drug targets.

AB - Functional genomics approaches can overcome limitations—such as the lack of identification of robust targets and poor clinical efficacy—that hamper cancer drug development. Here we performed genome-scale CRISPR–Cas9 screens in 324 human cancer cell lines from 30 cancer types and developed a data-driven framework to prioritize candidates for cancer therapeutics. We integrated cell fitness effects with genomic biomarkers and target tractability for drug development to systematically prioritize new targets in defined tissues and genotypes. We verified one of our most promising dependencies, the Werner syndrome ATP-dependent helicase, as a synthetic lethal target in tumours from multiple cancer types with microsatellite instability. Our analysis provides a resource of cancer dependencies, generates a framework to prioritize cancer drug targets and suggests specific new targets. The principles described in this study can inform the initial stages of drug development by contributing to a new, diverse and more effective portfolio of cancer drug targets.

UR - http://www.scopus.com/inward/record.url?scp=85064233743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064233743&partnerID=8YFLogxK

U2 - 10.1038/s41586-019-1103-9

DO - 10.1038/s41586-019-1103-9

M3 - Article

VL - 568

SP - 511

EP - 516

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7753

ER -